Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Lung Neoplasms 20Ovarian Neoplasms 15Carcinoma, Non-Small-Cell Lung 15Fallopian Tube Neoplasms 13Colorectal Neoplasms 10Pancreatic Neoplasms 9Carcinoma, Hepatocellular 9Melanoma 8Triple Negative Breast Neoplasms 7Squamous Cell Carcinoma of Head and Neck 7Breast Neoplasms 6Urinary Bladder Neoplasms 5Prostatic Neoplasms 5Neoplasm Metastasis 5Mycosis Fungoides 5Lymphoma, T-Cell, Cutaneous 5Carcinoma, Renal Cell 5Neoplasms 4Uterine Cervical Neoplasms 3Sezary Syndrome 3Sarcoma 3Myelodysplastic Syndromes 3Multiple Myeloma 3Lymphoma, T-Cell 3Leukemia, Myeloid, Acute 3Leukemia, Lymphocytic, Chronic, B-Cell 3Glioblastoma 3Endometrial Neoplasms 3Cholangiocarcinoma 3Carcinoma, Transitional Cell 3

Interventions

fludarabine phosphate 24Peripheral Blood Stem Cell Transplantation 21Cyclophosphamide 21Busulfan 19Whole-Body Irradiation 15Tacrolimus 15Mycophenolic Acid 13Methotrexate 12ruxolitinib 11Cyclosporine 10Antilymphocyte Serum 10fludarabine 8Melphalan 7peginterferon alfa-2a 6Aspirin 6Filgrastim 5Stem Cell Transplantation 4Radiotherapy 4Imatinib Mesylate 4Hydroxyurea 4Flow Cytometry 4Etoposide 4Decitabine 4Biopsy 4Azacitidine 4Thiotepa 3Surveys and Questionnaires 3Prednisone 3Methylprednisolone 3Injections 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Polycythemia Vera × Immunoglobulin G × Clear all
NCT02871323 2019-08-20

Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis

Northwestern University

Phase 1 Withdrawn
Myeloid

Polycythemia Vera, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡